1.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 19 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0103, 398-04FB, NCT00105053
|
|
2.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0104, OBA#0404-640, NCT00300612
|
|
3.
|
Phase: Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Other Protocol IDs: SVMC-ONC-222P, NCI-V96-0886, NCT00002773
|
|
4.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SVMC-ONC-222, NCI-V91-0075, NCT00002475
|
|
5.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 to 80 Sponsor: NCI, Other Protocol IDs: UKMC-IRB-0391-F2R, UKMC-CTRF-G-01-009, NCT00103116
|
|
6.
|
Phase: No phase specified Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: NCI-LUN-1
|
|
7.
|
Phase: No phase specified Type: Treatment Status: Closed Age: Under 70 Sponsor: Protocol IDs: RPMI-DMA-970701, NCI-D78-026-209
|
|
8.
|
Phase: No phase specified Type: Treatment Status: Closed Age: under 18 Sponsor: Protocol IDs: SJCRH-NB-1, SJCRH-NB-74
|
|
9.
|
Phase: No phase specified Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: SWE-LGMS-AML-1
|
|
10.
|
Phase: No phase specified Type: Treatment Status: Closed Age: no age specified Sponsor: Protocol IDs: UARIZ-IIIB
|
|
11.
|
Phase: No phase specified Type: Treatment Status: Closed Age: 5 to 70 Sponsor: Protocol IDs: UCLA-SAR-1
|